Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC9J1Y
|
|||
| Drug Name |
RO5461111
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Preclinical | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin S (CTSS) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Tuberculosis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | |||
| Trafficking and processing of endosomal TLR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015 Feb;74(2):452-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.